Dimerix Limited announced that the last patient has completed dosing in its clinical study in Focal Segmental Glomerulosclerosis (FSGS). No serious adverse events related to the drug have been reported to date and Dimerix expects to provide top line results for the study by end of July 2020. The Phase 2a study is a double-blind, randomised, placebo-controlled, crossover study designed to evaluate the safety and preliminary signs of efficacy of DMX-200 in patients with FSGS who are receiving a steady dose of an angiotensin receptor blocker, irbesartan. As previously announced, each participant in the study received 16 weeks DMX-200 and 16 weeks placebo, separated by a 6-week washout period. The primary endpoint for the study is safety, as measured by the number and severity of adverse events and clinically significant changes in the patient safety profile with the use of DMX-200 compared to placebo in participants with FSGS who are receiving irbesartan. The secondary endpoints include efficacy measures such as the percent change from baseline in 24-hour protein to creatinine ratio after 16-weeks of treatment with DMX-200 as compared to placebo and the proportion of patients who achieve a pre-defined reduction in proteinuria during treatment with DMX-200 as compared to placebo. Importantly, Dimerix has facilitated continued compassionate access to DMX-200 for multiple patients who have completed the study via their physician through the TGA Special Access Scheme. Dimerix has two Phase 2 studies underway: DMX-200 for FSGS; and DMX-200 for Diabetic Kidney Disease (last patient scheduled to receive last dose in July 2020), an asset in pre-clinical development, DMX-700 for chronic obstructive pulmonary disease (COPD), and a recently added new pivotal phase opportunity: DMX-200 in Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19.